Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis

Képénékian, Vahan; Aloy, Marie Thérèse; Magné, Nicolas; Passot, Guillaume; Armandy, Emma; Decullier, Évelyne; Sayag-Beaujard, A. C.; Gilly, François Noël; Gléhen, Olivier; Rodriguez-Lafrasse, Claire

doi:10.1007/s12192-013-0415-1

Cited by 13 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a mouse melanoma model, hyperthermia seemed to cause immunosuppressive effects and subsequently disease progression (35). Moreover, the enhanced systemic release of heat-shock proteins (HSPs) during HIPEC may result in reduced response to hyperthermia as well as chemotherapy (36)(37)(38)(39)(40). Additionally, HSPs have anti-apoptotic properties and promote tumor cell proliferation, invasiveness and metastatic dissemination (39,41).…”

Section: Discussionmentioning

confidence: 99%

Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?

et al. 2020

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?

et al. 2020

View full text Add to dashboard Cite

“…Furthermore, CRS plus HIPEC is now considered a standard treatment for several peritoneal carcinomas including colorectal and ovarian cancers (24,25). Although this multimodal approach improves the locoregional control of gastric cancer and ultimately increases the survival of patients with this disease, HIPEC treatment results in the activation of cellular stress responses; specifically, the expression of HSPs, rendering tumor cells partially thermotolerant and chemotolerant (13). Thus, elucidating the function of HSPs in tumor hyperthermia may further improve the performance of HIPEC-based treatments.…”

Section: Discussionmentioning

confidence: 99%

“…Transient hyperthermia treatment is able to induce the activation of cellular stress responses, specifically the upregulation of the expression of heat shock proteins (HSPs) (13). HSPs constitute a group of proteins induced by heat shock or cellular stress, which are able to inhibit the misfolding and aggregation of proteins in the cell.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: Indications for hyperthermic intraperitoneal chemoperfusion therapy

Tian

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Heat shock proteins (HSPs) are important factors in the response of cancer cells to thermo- and chemotherapy. Transient hyperthermic intraperitoneal chemoperfusion (HIPEC) therapy results in the upregulation of HSP expression, which may compromise the efficacy of additional anticancer treatments. The aim of the present study was to monitor the kinetics of HSP expression in tumor cells and patients with gastric cancer following HIPEC. Thus, and experiments were conducted to investigate the expression of two HSP family members, HSP70 and HSP90. Cells from two gastric tumor strains were subjected to HIPEC-mimicking treatment, and HSPs expression was analyzed at specific time points up to 48 h. Serum HSP concentrations were analyzed in patients with gastric cancer who had previously received cytoreductive surgery plus HIPEC treatment. The experiments indicated a significant elevation of HSP90 expression in gastric adenocarcinoma cells following hyperthermic treatment. However, HSP70 expression increased from 4 h up to 20 h post-exposure and decreased to normal levels 36 h post-exposure. Analysis of HSPs in serum samples collected from 22 patients with gastric cancer confirmed that serum HSP90 and HSP70 levels increased following HIPEC therapy, peaking at 18 h and returning to normal 24 h post-exposure. It is therefore advisable to apply the second round of HIPEC or chemotherapy at least 24 h following the first treatment to minimize any potential thermoresistance and chemoresistance of tumor cells.

show abstract

“…Also, due to the heat sink effect of the tumor blood vessels, the actual tissue temperature that can be reached is lower than that of the heated IP solution. Hyperthermia elicits the expression of heat shock proteins (HSP's), which were shown to exert anti-apoptotic and proliferative effects, and to induce resistance to chemotherapy [37,38]. Also, temperatures above 41 • C may cause scald injury to the peritoneum, which is already extensively damaged by the CRS [39].…”

Section: Use Of Hyperthermiamentioning

confidence: 99%

Hyperthermic Intraperitoneal Chemotherapy: A Critical Review

Ceelen

Demuytere

Hingh

2021

Cancers

View full text Add to dashboard Cite

With increasing awareness amongst physicians and improved radiological imaging techniques, the peritoneal cavity is increasingly recognized as an important metastatic site in various malignancies. Prognosis of these patients is usually poor as traditional treatment including surgical resection or systemic treatment is relatively ineffective. Intraperitoneal delivery of chemotherapeutic agents is thought to be an attractive alternative as this results in high tumor tissue concentrations with limited systemic exposure. The addition of hyperthermia aims to potentiate the anti-tumor effects of chemotherapy, resulting in the concept of heated intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal metastases as it was developed about 3 decades ago. With increasing experience, HIPEC has become a safe and accepted treatment offered in many centers around the world. However, standardization of the technique has been poor and results from clinical trials have been equivocal. As a result, the true value of HIPEC in the treatment of peritoneal metastases remains a matter of debate. The current review aims to provide a critical overview of the theoretical concept and preclinical and clinical study results, to outline areas of persisting uncertainty, and to propose a framework to better define the role of HIPEC in the treatment of peritoneal malignancies.

show abstract

Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis

Abstract: Despite the strong rationale for combining cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis, thermotolerance and chemoresistance might result from heat shock protein overexpression.

Cited by 13 publications

References 36 publications

Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?

Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?

Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: Indications for hyperthermic intraperitoneal chemoperfusion therapy

Hyperthermic Intraperitoneal Chemotherapy: A Critical Review

Contact Info

Product

Resources

About